Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

A Nonfimbrial Adhesin of Aggregatibacter actinomycetemcomitans Mediates Biofilm Biogenesis.

Danforth DR, Tang-Siegel G, Ruiz T, Mintz KP.

Infect Immun. 2018 Dec 19;87(1). pii: e00704-18. doi: 10.1128/IAI.00704-18. Print 2019 Jan.

PMID:
30297525
2.

Using Virtual Reality Simulation Environments to Assess Competence for Emergency Medicine Learners.

McGrath JL, Taekman JM, Dev P, Danforth DR, Mohan D, Kman N, Crichlow A, Bond WF.

Acad Emerg Med. 2018 Feb;25(2):186-195. doi: 10.1111/acem.13308. Epub 2017 Oct 11.

PMID:
28888070
3.

Effect of gonadotropin-releasing hormone antagonist on primordial follicle survival in the primate ovary.

Attaman J, Arbogast LK, Friedman CI, Danforth DR.

J Reprod Med. 2014 Mar-Apr;59(3-4):103-9.

PMID:
24724216
4.

Using second life virtual simulation environment for mock oral emergency medicine examination.

Schwaab J, Kman N, Nagel R, Bahner D, Martin DR, Khandelwal S, Vozenilek J, Danforth DR, Nelson R.

Acad Emerg Med. 2011 May;18(5):559-62. doi: 10.1111/j.1553-2712.2011.01064.x. Epub 2011 Apr 26.

5.

Neutralization of endogenous vascular endothelial growth factor depletes primordial follicles in the mouse ovary.

Roberts AE, Arbogast LK, Friedman CI, Cohn DE, Kaumaya PT, Danforth DR.

Biol Reprod. 2007 Feb;76(2):218-23. Epub 2006 Oct 18.

PMID:
17050862
6.

Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists.

Danforth DR, Arbogast LK, Friedman CI.

Fertil Steril. 2005 May;83(5):1333-8.

PMID:
15866565
7.

Vascular endothelial growth factor stimulates preantral follicle growth in the rat ovary.

Danforth DR, Arbogast LK, Ghosh S, Dickerman A, Rofagha R, Friedman CI.

Biol Reprod. 2003 May;68(5):1736-41. Epub 2002 Dec 11.

PMID:
12606430
8.

Inhibition of alkaline phosphatase activity of boar semen by pentoxifylline, caffeine, and theophylline.

Glogowski J, Danforth DR, Ciereszko A.

J Androl. 2002 Nov-Dec;23(6):783-92.

9.

Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone.

Seifer DB, Scott RT Jr, Bergh PA, Abrogast LK, Friedman CI, Mack CK, Danforth DR.

Fertil Steril. 1999 Jul;72(1):63-5.

PMID:
10428149
10.

Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential.

Friedman CI, Seifer DB, Kennard EA, Arbogast L, Alak B, Danforth DR.

Fertil Steril. 1998 Nov;70(5):836-9.

PMID:
9806563
11.

Dimeric inhibin: a direct marker of ovarian aging.

Danforth DR, Arbogast LK, Mroueh J, Kim MH, Kennard EA, Seifer DB, Friedman CI.

Fertil Steril. 1998 Jul;70(1):119-23.

PMID:
9660432
12.

Inhibin-B: the physiologic basis of the clomiphene citrate challenge test for ovarian reserve screening.

Hofmann GE, Danforth DR, Seifer DB.

Fertil Steril. 1998 Mar;69(3):474-7.

PMID:
9531880
13.

Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction.

Friedman CI, Danforth DR, Herbosa-Encarnacion C, Arbogast L, Alak BM, Seifer DB.

Fertil Steril. 1997 Oct;68(4):607-12.

PMID:
9341598
14.

Interleukin-1 beta modulates prostaglandin and progesterone production by primate luteal cells in vitro.

Young JE, Friedman CI, Danforth DR.

Biol Reprod. 1997 Mar;56(3):663-7.

PMID:
9047011
15.

Identification of gonadotrophin surge-inhibiting factor (GnSIF)/attenuin in human follicular fluid.

Mroueh JM, Arbogast LK, Fowler P, Templeton AA, Friedman CI, Danforth DR.

Hum Reprod. 1996 Mar;11(3):490-6.

PMID:
8671252
16.

Purification of a candidate gonadotropin surge inhibiting factor from porcine follicular fluid.

Danforth DR, Cheng CY.

Endocrinology. 1995 Apr;136(4):1658-65.

PMID:
7895676
17.

Endocrine and paracrine control of oocyte development.

Danforth DR.

Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):747-52. Review.

PMID:
7872376
18.

Ovarian control of follicle development.

Erickson GF, Danforth DR.

Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):736-47. Review.

PMID:
7872375
19.

In vivo effects of a potent GnRH antagonist ORG 30850: physiologic evidence that down-regulation of GnRH receptors does not occur.

Gordon K, Scott RT, Williams RF, Danforth DR, Loozen HJ, Kloosterboer HJ, Hodgen GD.

J Soc Gynecol Investig. 1994 Oct-Dec;1(4):290-6.

PMID:
9419786
21.

Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models.

Hodgen GD, van Uem JF, Chillik CF, Danforth DR, Wolf JP, Neulen J, Williams RF, Chwalisz K.

Hum Reprod. 1994 Jun;9 Suppl 1:77-81. Review.

PMID:
7962474
22.
23.
25.

GnRH antagonists suppress prolactin release in non-human primates.

Gordon K, Williams RF, Danforth DR, Veldhuis JD, Hodgen GD.

Contraception. 1992 Apr;45(4):369-78.

PMID:
1516369
26.

Antide bioavailability: single dose administration for suppression of testosterone and inhibin in male monkeys.

Edelstein MC, Gordon K, Williams RF, Danforth DR, Winters SJ, Hodgen GD.

Contraception. 1992 Feb;45(2):155-66.

PMID:
1559337
27.

Suppression of ovarian estradiol secretion by a single injection of antide in cynomolgus monkeys during the early follicular phase: immediate, sustained, and reversible actions.

Gordon K, Williams RF, Danforth DR, Conn PM, Hutchison JS, Hodgen GD.

J Clin Endocrinol Metab. 1991 Dec;73(6):1262-8.

PMID:
1955507
28.

Early folliculogenesis in primate ovaries: testing the role of estrogen.

Koering MJ, Danforth DR, Hodgen GD.

Biol Reprod. 1991 Dec;45(6):890-7.

PMID:
1805992
31.
32.
33.

Single dose long-term suppression of testosterone secretion by a gonadotropin-releasing hormone antagonist (Antide) in male monkeys.

Edelstein MC, Gordon K, Williams RF, Danforth DR, Hodgen GD.

Contraception. 1990 Aug;42(2):209-14.

PMID:
2085971
34.

In vivo and in vitro modulation of gonadotropin-releasing hormone metabolism by estradiol and progesterone.

Danforth DR, Elkind-Hirsch K, Hodgen GD.

Endocrinology. 1990 Jul;127(1):319-24.

PMID:
2193798
35.

Intermittent GnRH antagonist plus progestin contraception conserving tonic ovarian estrogen secretion and reducing progestin exposure.

Danforth DR, Williams RF, Hsiu JG, Roh SI, Hahn D, McGuire JL, Hodgen GD.

Contraception. 1990 Jun;41(6):623-31.

PMID:
2113850
36.
37.

Progesterone and 17 alpha-hydroxyprogesterone. Novel stimulators of calcium influx in human sperm.

Blackmore PF, Beebe SJ, Danforth DR, Alexander N.

J Biol Chem. 1990 Jan 25;265(3):1376-80.

38.

Probing studies on multiple dose effects of antide (Nal-Lys) GnRH antagonist in ovariectomized monkeys.

Leal JA, Gordon K, Williams RF, Danforth DR, Roh SI, Hodgen GD.

Contraception. 1989 Nov;40(5):623-33.

PMID:
2515029
39.

Effects of ovarian tissue reduction on the menstrual cycle: persistent normalcy after near-total oophorectomy.

Danforth DR, Chillik CF, Hertz R, Hodgen GD.

Biol Reprod. 1989 Aug;41(2):355-60.

PMID:
2508777
40.

Contraceptive potential of RU 486 by ovulation inhibition: III. Preliminary observations on once weekly oral administration.

Danforth DR, Dubois C, Ulmann A, Baulieu EE, Hodgen GD.

Contraception. 1989 Aug;40(2):195-200.

PMID:
2503298
41.

Contraceptive potential of RU 486 by ovulation inhibition: II. Suppression of pituitary gonadotropin secretion in vitro.

Wolf JP, Danforth DR, Ulmann A, Baulieu EE, Hodgen GD.

Contraception. 1989 Aug;40(2):185-93.

PMID:
2503297
42.

Contraceptive potential of RU 486 by ovulation inhibition: I. Pituitary versus ovarian action with blockade of estrogen-induced endometrial proliferation.

van Uem JF, Hsiu JG, Chillik CF, Danforth DR, Ulmann A, Baulieu EE, Hodgen GD.

Contraception. 1989 Aug;40(2):171-84.

PMID:
2503296
43.
44.

Gonadotropin-releasing hormone infusion interval: importance in pharmacodynamics.

Schmutzler R, Elkind-Hirsch K, Hahn D, McGuire JL, Simon JA, Danforth DR, Hodgen GD.

J Med Primatol. 1989;18(5):373-82.

PMID:
2681784
45.

Prolonged duration of gonadotropin inhibition by a third generation GnRH antagonist.

Leal JA, Williams RF, Danforth DR, Gordon K, Hodgen GD.

J Clin Endocrinol Metab. 1988 Dec;67(6):1325-7.

PMID:
3142920
46.
48.

Subcutaneous implantable infusion device for chronic intravenous pulsatile gonadotropin-releasing hormone treatment.

Schmutzler R, van Uem JF, Elkind-Hirsch K, Hahn D, McGuire JL, Danforth DR, Hodgen GD.

J Med Primatol. 1988;17(5):281-5.

PMID:
3068368
49.

Identification of gonadotropin surge-inhibiting factor (GnSIF) in follicular fluid and its differentiation from inhibin.

Danforth DR, Sinosich MJ, Anderson TL, Cheng CY, Bardin CW, Hodgen GD.

Biol Reprod. 1987 Dec;37(5):1075-82.

PMID:
3126837

Supplemental Content

Loading ...
Support Center